Physician

Michael R. Decker, MD

According to 2025 Medicare claims, Michael Decker, MD (NPI: 1861551491) practices endocrinology in the Portland-Vancouver-Hillsboro, OR-WA market, with the plurality of this provider's patient population coming from Clark, WA. This provider's primary affiliated billing organization is THE VANCOUVER CLINIC INC PS (NPI: 1992759427; TIN: 910851599) and primary practice location at 98664-1913. Decker is affiliated with the PSW ACO (ACO ID: A5323) and Humana Direct Contracting Entity, Inc. (ACO ID: D0203), participating under both the MSSP and REACH models.

Decker's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 344 traditional Medicare patients, billed 5,648 HCPCS/CPT codes, and received $126,395 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,915 prescription claims across 568 beneficiaries totaling $1,224,580 in drug costs, led by Jardiance (Empagliflozin). DME data shows 381 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $81,097 to $126,395. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $766,814 to $1,224,580. For DME billing, reported payments moved sharply higher in recent years, from $6,890 to $122,805.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	352	20,662	$81,097
2016	386	13,842	$89,157
2017	385	15,438	$85,901
2018	412	19,729	$114,483
2019	392	8,078	$111,802
2020	355	4,756	$95,278
2021	389	6,169	$133,901
2022	354	5,364	$113,380
2023	364	4,956	$112,427
2024	344	5,648	$126,395

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	352	3,566	$766,814
2016	362	3,520	$840,958
2017	409	3,768	$1,021,288
2018	437	4,005	$1,292,660
2019	467	4,210	$1,412,045
2020	496	4,180	$1,501,613
2021	537	4,080	$1,500,890
2022	530	3,504	$1,507,777
2023	518	4,020	$1,934,123
2024	568	3,915	$1,224,580

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	168	396	$10,032
2016	158	502	$27,738
2017	136	440	$40,940
2018	189	567	$64,935
2019	164	690	$98,222
2020	126	602	$85,699
2021	124	631	$100,174
2022	107	570	$97,625
2023	125	665	$125,870
2024	75	381	$124,825

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	221	344	$89
84443	Blood test, thyroid stimulating hormone (tsh)	136	184	$16
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	193	243	$12
83036	Hemoglobin a1c level	119	204	$9
36415	Insertion of needle into vein for collection of blood sample	256	529	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	169	12,850	$241,005
Trulicity	Dulaglutide	113	5,096	$170,780
Mounjaro	Tirzepatide	119	3,668	$134,730
Ozempic	Semaglutide	87	4,340	$134,211
Rybelsus	Semaglutide	42	1,620	$50,100

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	56	235	$106,958
J1817	Insulin for administration through dme (i.e., insulin pump) per 50 units	N	N/R	26	$5,962
A4224	Supplies for maintenance of insulin infusion catheter, per week	N	N/R	20	$4,808
E0784	External ambulatory infusion pump, insulin	Y	N/R	12	$4,030
A4225	Supplies for external insulin infusion pump, syringe type cartridge, sterile, each	N	N/R	24	$1,894

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Michael R. Decker, MD?

Tedicare shows public-source Medicare data for Michael R. Decker, MD (NPI 1861551491), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael R. Decker, MD have ACO affiliation data?

Michael R. Decker, MD is shown with ACO affiliation data for PSW ACO (MSSP, ACO ID A5323) and Humana Direct Contracting Entity, Inc. (REACH, ACO ID D0203).

What billing organization is linked to Michael R. Decker, MD?

Michael R. Decker, MD is linked to THE VANCOUVER CLINIC INC PS (billing NPI 1992759427) in the available physician profile data.

Does Michael R. Decker, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.